Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA)
Min Tian,
Yijia Hua,
Qian Liu,
Nan Jin,
Xinyu Wu,
Kun Wang,
Min Yan,
Tao Sun,
Chunfang Hao,
Yanxia Zhao,
Wei Li,
Xiang Huang,
Yongmei Yin
Wiley ·
2026-09-24
· DOI 10.1002/mog2.70096
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Min Tian, Yijia Hua, Qian Liu, Nan Jin, Xinyu Wu, Kun Wang et al. Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA). // MedComm - Oncology. – 2026. – DOI: 10.1002/mog2.70096. – URL: https://onlinelibrary.wiley.com/doi/10.1002/mog2.70096?af=R
Min Tian, Yijia Hua, Qian Liu, Nan Jin, Xinyu Wu, Kun Wang, Min Yan, Tao Sun, Chunfang Hao, Yanxia Zhao, Wei Li, Xiang Huang, & Yongmei Yin (2026). Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA). MedComm - Oncology. https://doi.org/10.1002/mog2.70096
Min Tian, et al. “Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA).” MedComm - Oncology, 2026. doi:10.1002/mog2.70096.
@article{Tian2026,
title = {Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA)},
author = {Tian, Min and Hua, Yijia and Liu, Qian and Jin, Nan and Wu, Xinyu and Wang, Kun and Yan, Min and Sun, Tao and Hao, Chunfang and Zhao, Yanxia and Li, Wei and Huang, Xiang and Yin, Yongmei},
journal = {MedComm - Oncology},
year = {2026},
doi = {10.1002/mog2.70096},
url = {https://onlinelibrary.wiley.com/doi/10.1002/mog2.70096?af=R}
}